Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.
Hodgkin's Lymphoma
DRUG: Resminostat (4SC-201)
Determination of the best overall objective response rate (ORR) based on IWG criteria of Resminostat (4SC-201) in patients with refractory or relapsed Hodgkin's Lymphoma., 12 weeks
Investigation of the safety and tolerability of repeated oral doses of Resminostat (4SC-201), 12 weeks|Assessment of the overall survival (OS), 12 weeks|Determination of progression free survival (PFS), including radiological and symptomatic progression, 12 weeks|Determination of time to progression (TTP), including objective and symptomatic progression, 12 weeks|Determination of duration of response (DOR), 12 weeks|Assessment of the pharmacokinetics of Resminostat (4SC-201) after oral dosing, 12 weeks
The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.